查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
异位性皮肤炎市场:KOL的洞察
市场调查报告书
商品编码
1789646

异位性皮肤炎市场:KOL的洞察

KOL Insight - Atopic Dermatitis
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告基于对美国和欧洲领先的皮肤科关键人事官 (KOL) 的访谈，对中度至重度异位性皮肤炎治疗格局的演变进行了深入的定性分析。本报告探讨了专家对新上市和在研疗法的看法，重点关注 Evgris 的崛起、对 Nemrubio 的不同看法，以及安丽单抗与其他新兴疗法的相对定位。专家洞察包括当前的处方趋势、重要的临床考虑因素以及新数据发布后的市场变化。

关键问题解答：

  • 1.Dupixent 目前在异位性皮肤炎的应用情况如何？
  • 2.近期上市的最有前景的异位性皮肤炎疗法有哪些？它们的作用机转是什么？
  • 3.哪些在研疗法预计会影响异位性皮肤炎治疗？
  • 4.影响当前和未来处方趋势的关键临床试验。
  • 5.与现有疗法相比，专家如何看待新兴疗法的疗效和安全性？
  • 6.哪些因素正在推动或限制新型异位性皮肤炎药物的采用？
  • 7.KOL 预计中度至重度异位性皮肤炎的治疗方案将如何发展？
  • 8.中度至重度异位性皮肤炎的治疗中有哪些未满足的需求？
  • 9.患者的特征和严重程度如何影响全身性治疗的选择？
  • 10.预计新疗法将对目前异位性皮肤炎的市场领导者产生哪些影响？

主要品牌

  • Dupixent
  • Evglis
  • Adbry/Adtraza
  • Cybainco
  • Rimboq
  • Nemrubio

部分参与品牌名单专家

  • 加州大学旧金山分校皮肤病学教授
  • 北卡罗来纳州温斯顿-塞勒姆维克森林大学医学院皮肤病学、病理学和公共卫生科学教授
  • 路易斯维尔大学医学院皮肤病学临床教授
  • 义大利维罗纳大学皮肤病学教授
  • 法国图卢兹保罗‧萨巴蒂尔大学皮肤病学教授
  • 索尔福德皇家NHS基金会皮肤病学教授兼顾问皮肤科医生

方法：

"治疗趋势" 报告透过对全球领先的关键意见领袖 (KOL) 进行深入访谈，探讨关键疾病领域的当前和未来治疗前景。我们根据严格的标准精心挑选关键意见领袖 (KOL)，这些标准包括全球声誉、临床专业知识以及在治疗领域的影响力。每次访谈都附有精心设计的讨论指南。这些指南由我们与关键意见领袖合作开发，并由行业专家进行同行评审，确保问题全面且与当前市场动态相关。每份报告发布后，我们会持续 12 个月的市场监测，及时提供关键意见领袖对重要新闻事件、市场变化和市场发展的更新。

我们报告的特点

FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供深入、可操作的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助我们的客户掌握新兴趋势并有效解决复杂课题。凭藉广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家专访和数据，结合持续的市场监测，确保您全面洞察市场动态。我们的报告涵盖 40 多个活跃疾病领域，包含 KOL 洞察和定量医生调查等医生情报，以及行业专家对医疗事务、数位健康、销售与行销、市场准入及其他领域问题的看法，助您做出更明智的数据驱动决策，在快速变化的行业中保持竞争力。

简介目录

This report provides an in-depth qualitative analysis of the evolving treatment landscape for moderate-to-severe atopic dermatitis, based on interviews with leading dermatology KOLs across the US and Europe. It examines expert perceptions of newly launched and pipeline therapies, with particular attention to the rise in Ebglyss, mixed views on Nemluvio, and how amlitelimab is positioned relative to other emerging agents. Gain expert insights on current prescribing trends, key clinical considerations, and how the market may shift as new data become available.

Key Questions Answered:

  • 1. How is Dupixent currently used in atopic dermatitis, and how might its prescribing change in the future?
  • 2. Which recently launched therapies and mechanisms of action are most promising for atopic dermatitis?
  • 3. Which pipeline products are expected to impact the atopic dermatitis treatment landscape?
  • 4. What are the key clinical trials influencing current and future prescribing trends?
  • 5. How do experts view the efficacy and safety of new and emerging therapies compared to established treatments?
  • 6. What factors are driving or limiting the uptake of new atopic dermatitis therapies?
  • 7. How do KOLs expect the treatment algorithm for moderate-to-severe atopic dermatitis to evolve?
  • 8. What are the main unmet needs in the management of moderate-to-severe atopic dermatitis?
  • 9. How do patient characteristics and disease severity influence systemic therapy selection?
  • 10. What is the anticipated impact of new therapies on current market leaders in atopic dermatitis?

Key Brands:

  • Dupixent
  • Ebglyss
  • Adbry/Adtralza
  • Cibinqo
  • Rinvoq
  • Nemluvio

Partial List of Participating Experts:

  • Professor of Dermatology at the University of California San Francisco, San Francisco, CA.
  • Professor of Dermatology, Pathology, and Public Health Sciences at Wake Forest University School of Medicine, Winston-Salem, NC.
  • Clinical Professor of Dermatology at the University of Louisville School of Medicine, Louisville, KY.
  • Professor of Dermatology at the University of Verona, Verona, Italy.
  • Professor of Dermatology at Paul Sabatier University, Toulouse, France.
  • Professor of Dermatology and Consultant Dermatologist at Salford Royal NHS Foundation Trust; and Director of the Dermatopharmacology Unit at the University of Manchester, Manchester, UK.

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.